Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 8-14 , January 2008

Agonistic antibodies directed at cell surface receptors and cardiovascular disease

Received 20 June 2007 ,Accepted 20 August 2007.

References 

  1. Kim-Saijo M, Akamizu T, Ikuta K, Iida Y, Ohmori K, Matsubara K, et al. Generation of a transgenic animal model of hyperthyroid Graves’ disease. Eur J Immunol. 2003;33:2531–2538
  2. Fareau GG, Maldonado M, Oral E, Balasubramanyam A. Regression of acanthosis nigricans correlates with disappearance of anti-insulin receptor autoantibodies and achievement of euglycemia in type B insulin resistance syndrome. Metabolism. 2007;56:670–675
  3. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene. 2007;26:3745–3757
  4. Bartholdy C, Kauffmann SO, Christensen JP, Thomsen AR. Agonistic anti–CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus. J Immunol. 2007;178:1662–1670
  5. Fu ML, Wallukat G, Hjalmarson A, Hoebeke J. Characterization of anti-peptide antibodies directed against an extracellular immunogenic epitope on the human alpha 1–adrenergic receptor. Clin Exp Immunol. 1994;97:146–151
  6. Fu ML, Herlitz H, Wallukat G, Hilme E, Hedner T, Hoebeke J, et al. Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension. Lancet. 1994;344:1660–1663
  7. Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension. 1997;29:678–682
  8. Wallukat G, Wollenberger A. Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta. 1987;46:S634–S639
  9. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy (Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect). Circulation. 1994;89:2760–2767
  10. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. [Erratum in: J Mol Cell Cardiol 1995;27:2529] J Mol Cell Cardiol. 1995;27:397–406
  11. Ferrari I, Levin MJ, Wallukat G, Elies R, Lebesgue D, Chiale P, et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med. 1995;182:59–65
  12. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a beta 1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429
  13. Störk S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J. 2006;152:697–704
  14. Staudt A, Staudt Y, Dorr M, Bohm M, Knebel F, Hummel A, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy. J Am Coll Cardiol. 2004;44:829–836
  15. Müller J, Wallukat G, Dandel M, Bieda H, Brandes K, Spiegelsberger S, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101:385–391
  16. Podlowski S, Luther HP, Morwinski R, Müller J, Wallukat G. Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation. 1998;98:2470–2476
  17. Staudt A, Hummel A, Ruppert J, Dorr M, Trimpert C, Birkenmeier K, et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J. 2006;152:712.e1–712.e6
  18. Fu ML, Schulze W, Wallukat G, Elies R, Eftekhari P, Hjalmarson A, et al. Immunohistochemical localization of angiotensin II receptors (AT1) in the heart with anti-peptide antibodies showing a positive chronotropic effect. Receptors Channels. 1998;6:99–111
  19. Fu ML, Leung PS, Wallukat G, Bergstrom G, Fu H, Schulze W, et al. Agonist-like activity of antibodies to angiotensin II receptor subtype 1 (AT1) from rats immunized with AT1 receptor peptide. Blood Press. 1999;8:317–324
  20. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, et al. Patients with pre-eclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945–952
  21. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens. 2000;18:945–953
  22. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, et al. AT1 receptor agonistic antibodies from pre-eclamptic patients stimulate NADPH oxidase. Circulation. 2003;107:1632–1639
  23. Bohlender J, Ganten D, Luft FC. Rats transgenic for human renin and human angiotensinogen as a model for gestational hypertension. J Am Soc Nephrol. 2000;11:2056–2061
  24. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Brasen JH, et al. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of pre-eclampsia. Hypertension. 2005;45:742–746
  25. Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from pre-eclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Investig. 2003;10:82–93
  26. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC, Xia Y, et al. Antibodies from pre-eclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation. 2004;110:1612–1619
  27. Bobst SM, Day MC, Gilstrap LC, Xia Y, Kellems RE. Maternal autoantibodies from pre-eclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor–1 secretion. Am J Hypertens. 2005;18:330–336
  28. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, et al. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res. 2007;100:88–95
  29. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, Roberts JM, et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of pre-eclampsia. Hypertension. 2007;49:612–617
  30. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, et al. Dysregulation of the circulating and tissue-based renin-angiotensin system in pre-eclampsia. Hypertension. 2007;49:604–611
  31. Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005;46:1275–1279
  32. Stepan H, Faber R, Wessel N, Wallukat G, Schultheiss HP, Walther T. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J Clin Endocrinol Metab. 2006;91:2424–2427
  33. Stepan H, Wallukat G, Schultheiss HP, Faber R, Walther T. Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor?. J Reprod Immunol. 2007;73:130–134
  34. Dragun D, Müller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352:558–569
  35. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667–2676
  36. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood. 2007;110:237–241
  37. Collins J, Gough S. Autoimmunity in thyroid disease. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S417–S424
  38. Venter JC, Fraser CM. Beta-adrenergic receptor structure, synthesis, antibodies and human disease. Bull Eur Physiopathol Respir. 1985;21:13S–18S
  39. Schroeder C, Vernino S, Birkenfeld AL, Tank J, Heusser K, Lipp A, et al. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. 2005;353:1585–1590
  40. Nikolaev VO, Boivin V, Stork S, Angermann CE, Ertl G, Lohse MJ, et al. A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol. 2007;50:423–431
  41. Pendergraft WF, Pressler BM, Jennette JC, Falk RJ, Presont GA. Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med. 2005;83:12–25
  42. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M. Mapping the theories of pre-eclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol. 2007;109:168–180
  43. Scornik JC, Guerra G, Schold JD, Srinivas TR, Dragun D, Meier-Kriesche HU. Value of post-transplant antibody testing in the evaluation of patients with renal graft dysfunction. Am J Transplant. 2007;7:1808–1814
  44. Tachikawa K, Briggs SP. Targeting the human genome. Curr Opin Biotechnol. 2006;17:659–665
  45. Xia Y, Ramin SM, Kellems RE. Potential roles of angiotensin receptor-activating antibody in the pathophysiology of pre-eclampsia. Hypertension. 2007;50:269–275

 The Deutsche Forschungsgemeinschaft has supported the work of Drs. Luft and Müller. Further support for this work has been provided by the Bundesministerium für Bildung und Forschung.

 Conflict of interest: none.

PII: S1933-1711(07)00170-2

doi: 10.1016/j.jash.2007.08.005

Journal of the American Society of Hypertension
Volume 2, Issue 1 , Pages 8-14 , January 2008

Article Tools

* Image Usage & Resolution